A leukemia drug developed at The Ohio State University Comprehensive Cancer Center gets the approval from the federal government.
This is the Food and Drug Administration's first full approval of targeted drug therapy called Acalabrutinib for chronic lymphocytic leukemia (CLL) and small cell lymphoma (SCL). It will be marketed under the name “Calquence.“
Dr. John C. Byrd leads a team of researchers OSUCCC and ran clinical trials in collaboration with the College of Veterinary Medicine and the Comparative and Translation Oncology Program at Ohio State.
The research on Acalabrutinib was supported by a number of organizations including the National Cancer Institute, Leukemia and Lymphoma Society, and Pelotonia.
Acalabrutinib has been found to work by binding up the Bruton tyrosine kinase inhibitor (BTK).
It is part of a chain of proteins that carries growth signals from the surface of the cancer cell to genes in the cell nucleus which helps the cancer cells grow.